TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 340945

Group type: EXPERIMENTAL
Intervention: terbutaline 5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: aminophylline 400 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: terbutaline 5 mg plus aminophylline 400 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: terbutaline 2.5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: aminophylline 200 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: terbutaline 2.5 mg plus aminophylline 200 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 30986115

Group type: EXPERIMENTAL
Intervention: Isometric squat exercise against low load
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isometric squat exercise against medium load
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isometric squat exercise against high load
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Recovery period of 10 seconds after exercise
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Comparison between men and women during high load condition
Number of subjects: 26
Study: 28110911

Group type: EXPERIMENTAL
Intervention: 0.5 mg semaglutide
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: 1.0 mg semaglutide
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 25968008

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD) for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gluten-containing diet (control)
Number of subjects: 0
Study: 23565239

Group type: EXPERIMENTAL
Intervention: Emotion suppression (self-control task)
Number of subjects: 0
Study: 21886067

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bid, Amoxicillin 1 g bid, Clarithromycin 500 mg bid (LAC) for 14 days
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid, Levofloxacin 500 mg bid, Amoxicillin 1 g bid (OLA) for 7 days
Number of subjects: 91
Study: 19697537

Group type: EXPERIMENTAL
Intervention: Protocol I (terminal cleaning, inspection and admission of new patient(s))
Number of subjects: 31

Group type: COMPARATOR
Intervention: Protocol II (terminal cleaning, environmental cultures and closing of the room pending negative results)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Protocol II (environmental cultures)
Number of subjects: 31
Study: 16996194

Group type: EXPERIMENTAL
Intervention: Biphasic waveform (Welch Allyn‐MRL PIC defibrillator; 70, 100, 150, 200, and 300 J)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Monophasic waveform (HP Codemaster XL; 100, 200, 300, 360, and 360 J)
Number of subjects: 139
Study: 12749965

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (50 microg/kg/min over 60min)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine
Number of subjects: 23
Study: 12567694

Group type: EXPERIMENTAL
Intervention: Co-artemether
Number of subjects: 150

Group type: COMPARATOR
Intervention: Benflumetol tablet
Number of subjects: 150

Group type: COMPARATOR
Intervention: Benflumetol capsule
Number of subjects: 150
Study: 9347391

Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 169

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 169
Study: 8467249

Group type: EXPERIMENTAL
Intervention: Retinol (25,000 IU/day) for 48 to 65 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 3797879

Group type: EXPERIMENTAL
Intervention: Amoxycillin 40 mg/kg/day three times daily
Number of subjects: 367

Group type: COMPARATOR
Intervention: Amoxycillin 40 mg/kg/day two times daily
Number of subjects: 367
Study: 30377755

Group type: EXPERIMENTAL
Intervention: Inferior mesenteric vein (IMV) approach with systematic medial mobilization (MM)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Inferior mesenteric artery (IMA) approach
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both approaches (IMV and IMA)
Number of subjects: 98
Study: 29778129

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy (smelled two times daily for 20 min during 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (diluted milk)
Number of subjects: 100
Study: 27114593

Group type: EXPERIMENTAL
Intervention: ABVD (8 cycles)
Number of subjects: 549

Group type: COMPARATOR
Intervention: BEACOPP (4 cycles escalated + 4 cycles baseline)
Number of subjects: 549
Study: 25524333

Group type: EXPERIMENTAL
Intervention: Prasugrel pre-treatment (30-mg loading dose)
Number of subjects: 4033

Group type: COMPARATOR
Intervention: Placebo (no pre-treatment)
Number of subjects: 4033
Study: 23157722

Group type: EXPERIMENTAL
Intervention: Thin girls compared to normal-weight girls
Number of subjects: 5226

Group type: EXPERIMENTAL
Intervention: Overweight girls compared to normal-weight girls
Number of subjects: 5226

Group type: EXPERIMENTAL
Intervention: Obese girls compared to normal-weight girls
Number of subjects: 5226

Group type: EXPERIMENTAL
Intervention: Thin boys compared to normal-weight boys
Number of subjects: 5226

Group type: EXPERIMENTAL
Intervention: Overweight boys compared to normal-weight boys
Number of subjects: 5226

Group type: EXPERIMENTAL
Intervention: Obese boys compared to normal-weight boys
Number of subjects: 5226
Study: 20215968

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 5752

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5752
Study: 17118830

Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Blockade (SGB) in Group 1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 50
Study: 15300117

Group type: EXPERIMENTAL
Intervention: High-Dk silicone hydrogel lenses
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low-Dk hydrogel lenses
Number of subjects: 92
Study: 11207518

Group type: EXPERIMENTAL
Intervention: 5-day RACM regimen (rabeprazole 20 mg b.d., amoxicillin 750 mg b.d., clarithromycin 200 mg b.d., metronidazole 250 mg b.d.)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 7-day RAC regimen (rabeprazole 20 mg b.d., amoxicillin 750 mg b.d., clarithromycin 200 mg b.d.)
Number of subjects: 160
Study: 9297192

Group type: EXPERIMENTAL
Intervention: Platelet aggregation measured with ADP 5 microM; collagen 2 micrograms/ml; arachidonic acid 0.75 microM; serotonin 1 microM; ristocetin 1.5 micrograms/ml
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Plasma serotonin concentration in uremic patients
Number of subjects: 16
Study: 8341175

Group type: EXPERIMENTAL
Intervention: Carbimazole 30 mg once daily (group 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Carbimazole 15 mg twice daily (group 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Carbimazole 10 mg thrice daily (group 3)
Number of subjects: 70
Study: 3550043

Group type: EXPERIMENTAL
Intervention: Controlled extracapsular surgery with careful cleaning of the cortical material and in-the-bag implantation of a posterior chamber intraocular lens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior chamber angle‐fixated lenses with flexible loops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posterior chamber lenses placed in the ciliary sulcus and in the bag
Number of subjects: 0
Study: 29621945

Group type: EXPERIMENTAL
Intervention: Empathy intervention
Number of subjects: 0
Study: 29455676

Group type: EXPERIMENTAL
Intervention: Ophthalmoscopy simulator training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 17
Study: 27116983

Group type: EXPERIMENTAL
Intervention: Domestic rhFSH (n=352)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Imported rhFSH (n=179)
Number of subjects: 531
Study: 24477825

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Video‐assisted laryngoscope
Number of subjects: 40
Study: 22548962

Group type: EXPERIMENTAL
Intervention: Diet + aerobic exercise
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Diet + resistance exercise
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Diet + combined aerobic and resistance exercise
Number of subjects: 304

Group type: COMPARATOR
Intervention: Diet only waiting-list control
Number of subjects: 304
Study: 20509780

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention Group (EIG)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 869
Study: 18692244

Group type: EXPERIMENTAL
Intervention: argon laser trabeculoplasty plus betaxolol
Number of subjects: 255

Group type: COMPARATOR
Intervention: no initial treatment
Number of subjects: 255
Study: 17363538

Group type: EXPERIMENTAL
Intervention: Indisulam (700 mg/m2 as a single i.v. dose on day one)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Indisulam (130 mg/m2 given on days 1 to 5 as a daily infusion)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Indisulam (both treatment schedules)
Number of subjects: 44
Study: 12578340

Group type: EXPERIMENTAL
Intervention: Minimally invasive aortic valve replacement (partial upper sternotomy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional aortic valve replacement (complete median sternotomy)
Number of subjects: 40
Study: 11132373

Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron twice-weekly for 12 months
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 9080738

Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride mouthwash
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 129
Study: 8336992

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Octreotide (500 micrograms/day and 1500 micrograms/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Octreotide (50 micrograms s.c.)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Octreotide (double-blind check)
Number of subjects: 2
Study: 3087677

Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 9
Study: 29327104

Group type: EXPERIMENTAL
Intervention: Spa therapy added to usual pharmacotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual pharmacotherapy alone
Number of subjects: 0
Study: 27871559

Group type: EXPERIMENTAL
Intervention: Balanced anesthesia (remifentanil + sevoflurane)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (remifentanil + propofol)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Balanced anesthesia
Number of subjects: 130

Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 130
Study: 23877585

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Paper Questionnaire (PQ)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Personal Computer (PC)
Number of subjects: 923
Study: 23548697

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20865580

Group type: EXPERIMENTAL
Intervention: 50 mg intravenous dexketoprofen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups received standard anesthetic protocol and IV morphine via PCA
Number of subjects: 50
Study: 18927140

Group type: EXPERIMENTAL
Intervention: Family CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual CBT
Number of subjects: 0
Study: 16642606

Group type: EXPERIMENTAL
Intervention: Acupuncture at 'Kaiyin point No. 1', once daily for 7 days.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Spray inhalation of western medicine, once daily for 7 days.
Number of subjects: 160
Study: 14657775

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 12
Study: 11108404

Group type: EXPERIMENTAL
Intervention: Educational intervention (three-day workshop with lectures, videos, role-plays, interviews, demonstrations)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 149
Study: 8977750

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.) followed 120 minutes later by hexarelin (1 microgram/kg i.v.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hexarelin (1 microgram/kg i.v.) followed 120 minutes later by GHRH (1 microgram/kg i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.) followed 120 minutes later by GHRH (1 microgram/kg i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hexarelin (1 microgram/kg i.v.) followed 120 minutes later by hexarelin (1 microgram/kg i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH (0.5 IU i.v.) followed 120 minutes later by GHRH (1 microgram/kg i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH (0.5 IU i.v.) followed 120 minutes later by hexarelin (1 microgram/kg i.v.)
Number of subjects: 18
Study: 1623513

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6482920

Group type: EXPERIMENTAL
Intervention: Cefoxitin alone
Number of subjects: 145

Group type: COMPARATOR
Intervention: Clindamycin and gentamicin together
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Postoperative sepsis
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Risk factors for infection
Number of subjects: 145
Study: 31775418

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA) with 0.25% lidocaine and 1.33% lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: General Anesthesia (GA) with propofol, sufentanil, and cisatracurium
Number of subjects: 120
Study: 28254671

Group type: EXPERIMENTAL
Intervention: Improvement in Neck Disability Index (NDI) score at 24 months
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Absolute NDI score at 24 months
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Absolute VAS neck pain score at 24 months
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Improvement in NDI score at 60 months
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Absolute NDI score at 60 months
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Improvement in VAS neck pain score at 60 months
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Absolute VAS neck pain score at 60 months
Number of subjects: 512
Study: 25179578

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 0
Study: 23829039

Group type: EXPERIMENTAL
Intervention: Wearable interface
Number of subjects: 8

Group type: COMPARATOR
Intervention: Desktop simulator
Number of subjects: 8

Group type: COMPARATOR
Intervention: Interactive training video
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Live training environment
Number of subjects: 8
Study: 23055414

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg) with mirtazapine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg) with placebo
Number of subjects: 43
Study: 18793768

Group type: EXPERIMENTAL
Intervention: Laser zona thinning
Number of subjects: 84
Study: 16935794

Group type: EXPERIMENTAL
Intervention: 5% Vitreoscilla filiformis (V.f.) extract-containing ointment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 13
Study: 15347562

Group type: EXPERIMENTAL
Intervention: SDB (apnea-hypopnea index > or = 5) in men
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: SDB (apnea-hypopnea index > or = 5) in women
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: OSAS (apnea-hypopnea index > or = 5 plus excessive daytime sleepiness) in men
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: OSAS (apnea-hypopnea index > or = 5 plus excessive daytime sleepiness) in women
Number of subjects: 457
Study: 11502788

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (Premarin, 0.625 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9009974

Group type: EXPERIMENTAL
Intervention: CCNW plan (prepackaged meals)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Self-selected diet (AHA Step I and II)
Number of subjects: 560
Study: 8518245

Group type: EXPERIMENTAL
Intervention: Transdermally applied oestradiol (50 micrograms/24 h)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transdermally applied oestradiol (100 micrograms/24 h)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate (5 mg daily)
Number of subjects: 52
Study: 3450443

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30259145

Group type: EXPERIMENTAL
Intervention: ACL injury prevention program (ACL‐IPP) for 6 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-responders to ACL injury prevention program (ACL‐IPP)
Number of subjects: 43
Study: 31026242

Group type: EXPERIMENTAL
Intervention: I‐ON CXL (iontophoretic transepithelial collagen cross-linking)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Epi‐off CXL (epithelium-off collagen cross-linking)
Number of subjects: 28
Study: 29234748

Group type: EXPERIMENTAL
Intervention: Calcium‐incorporated titanium implants (Xpeed)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control resorbable blasted media (RBM) implants
Number of subjects: 60
Study: 25277347

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-Lymphocyte Ratio (NLR)
Number of subjects: 3262

Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 3262
Study: 23537965

Group type: EXPERIMENTAL
Intervention: Clinical pharmacy specialist-, telephone-administered intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22090661

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg on alternate days
Number of subjects: 27939

Group type: EXPERIMENTAL
Intervention: Prediction-based treatment using the newly developed model
Number of subjects: 27939

Group type: EXPERIMENTAL
Intervention: Selective treatment of women >65 years of age
Number of subjects: 27939

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 27939

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 27939

Group type: EXPERIMENTAL
Intervention: Current smoking and baseline risk for cardiovascular events
Number of subjects: 27939

Group type: EXPERIMENTAL
Intervention: Aspirin treatment strategy
Number of subjects: 27939
Study: 19673814

Group type: EXPERIMENTAL
Intervention: music-supported therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: standard rehabilitation procedures
Number of subjects: 32
Study: 16465651

Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy (oral tetracycline 250 mg twice daily, 3 times per week, and intravenous clindamycin infused on 5 consecutive days with varying dosages followed by weekly and fortnightly infusions for 12 months)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: No additional therapy (control group)
Number of subjects: 21
Study: 15057737

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 56 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 56 days with eradication of H. pylori during the last week of treatment
Number of subjects: 32
Study: 11902249

Group type: EXPERIMENTAL
Intervention: Lisofylline (3 mg/kg, max 300 mg IV every 6 hrs for 20 days or until 48 hrs of unassisted breathing)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Lisofylline
Number of subjects: 235
Study: 9673781

Group type: EXPERIMENTAL
Intervention: Oral BDP (0.2, 0.5, 1, 2 or 5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inhaled HFA BDP (0.2 or 0.8 mg)
Number of subjects: 40
Study: 7643880

Group type: EXPERIMENTAL
Intervention: Active management of labor
Number of subjects: 1934

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1934
Study: 2502168

Group type: EXPERIMENTAL
Intervention: Thiopentone 4 mg kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketamine 1.5 mg kg‐1
Number of subjects: 50
Study: 953956

Group type: EXPERIMENTAL
Intervention: Methyl-CCNU and vincristine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Methyl-CCNU, vincristine, and methotrexate
Number of subjects: 92

Group type: COMPARATOR
Intervention: Methyl-CCNU alone
Number of subjects: 92
Study: 29687232

Group type: EXPERIMENTAL
Intervention: English double-embedded sentences without middle verb phrase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dutch double-embedded sentences without middle verb phrase
Number of subjects: 0
Study: 28709470

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training with oxytocin administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cognitive Bias Modification (CBM) training with placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo training with oxytocin administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo training with placebo
Number of subjects: 100
Study: 24931003

Group type: EXPERIMENTAL
Intervention: Maca (3.3 g/day for 6 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (for 6 weeks)
Number of subjects: 29
Study: 23814237

Group type: EXPERIMENTAL
Intervention: MoM
Number of subjects: 397

Group type: COMPARATOR
Intervention: MoP
Number of subjects: 397

Group type: COMPARATOR
Intervention: CoP
Number of subjects: 397
Study: 22196062

Group type: EXPERIMENTAL
Intervention: 6% sevoflurane with 4 L/min O₂ for 3 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (non-sevoflurane) with 4 L/min O₂ alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (sevoflurane and non-sevoflurane)
Number of subjects: 30
Study: 18676056

Group type: EXPERIMENTAL
Intervention: 20Gy of radiation in 2 weeks followed by two courses of chemotherapy (paclitaxel 180mg/m², cisplatin 45mg/m², ifosfamide 1000mg/m²)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Completion radiotherapy of additional 45Gy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Median survival for patients with stages IB, IIA, and IIB
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Median survival for patients with stages IIIA and IIIB
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Treatment related morbidity
Number of subjects: 35